<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

[X]       Quarterly  Report  pursuant  to  Section 13 or 15(d) of the Securities
          Exchange  Act  of  1934

          For  the  quarterly  period  ended  November  30,  2002

[   ]     Transition  Report  pursuant to 13 or 15(d) of the Securities Exchange
          Act  of  1934

          For  the  transition  period                 to


          Commission  File  Number          000-33389
                                            ---------

                          AUGUST BIOMEDICAL CORPORATION
          -----------------------------------------------------------------
          (Exact name of small Business Issuer as specified in its charter)

NEVADA                                     52-2268239
-------------------------------            ---------------------------------
(State or other jurisdiction of            (IRS Employer Identification No.)
incorporation  or  organization)

SUITE  L-8,  601  W.  BROADWAY
VANCOUVER,  BRITISH  COLUMBIA,  CANADA     V5Z  4C2
----------------------------------------   ---------
(Address of principal executive offices)   (Zip Code)

Issuer's  telephone  number,
 including  area  code:                    (604)  608-3831
                                           ---------------

                         COYOTE  VENTURES  CORP.
                         -----------------------
              (Former name, former address and former fiscal year,
                          if changed since last report)

Check  whether  the issuer (1) filed all reports required to be filed by Section
13  or  15(d)  of  the  Securities  Exchange Act of 1934 during the preceding 12
months  (or  for  such  shorter period that the issuer was required to file such
reports),  and  (2) has been subject to such filing requirements for the past 90
days  [  X  ]  Yes    [  ]  No

State the number of shares outstanding of each of the issuer's classes of common
stock,  as  of  the  latest  practicable date: 12,025,000 Shares of Common Stock
outstanding  as  of  November  30,  2002.

<PAGE>


                         PART 1 - FINANCIAL INFORMATION

Item  1.          Financial  Statements

The  accompanying  un-audited  financial  statements  have  been  prepared  in
accordance  with  the instructions to Form 10-QSB and, therefore, do not include
all information and footnotes necessary for a complete presentation of financial
position,  results  of  operations,  cash  flows,  and  stockholders' deficit in
conformity  with  generally  accepted  accounting principles.  In the opinion of
management,  all adjustments considered necessary for a fair presentation of the
results  of  operations  and  financial position have been included and all such
adjustments  are  of a normal recurring nature.  Operating results for the three
months  ended  November  30,  2002 are not necessarily indicative of the results
that  can  be  expected  for  the  year  ending  August  31,  2003.


<PAGE>




                              COYOTE VENTURES CORP.
                          (A Development Stage Company)


                    CONSOLIDATED INTERIM FINANCIAL STATEMENTS


                                NOVEMBER 30, 2002
                                   (Unaudited)
                            (Stated in U.S. Dollars)



<PAGE>



                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                           CONSOLIDATED BALANCE SHEET
                            (Stated in U.S. Dollars)


<TABLE>
<CAPTION>

--------------------------------------------------------------------------------

                              NOVEMBER 30    AUGUST 31
                                     2002        2002
-------------------------------------------------------
                                  (Unaudited) (Audited)
<S>                               <C>         <C>

ASSETS

Current
  Cash                            $ 112,262   $ 183,608
  Advances receivable                 1,500           -
  Prepaid expenses                    1,088       1,554
                                  ----------  ----------

                                    114,850     185,162
Equipment (Note 4)                   25,500      10,991
Intangible Assets (Note 5)           40,000      20,000

                                  ----------  ----------

                                  $ 180,350   $ 216,153
=========================================================



LIABILITIES

Current
  Accounts payable and
  accrued liabilities             $  36,590   $  49,591
  Due to shareholder                 20,000           -
                                  ----------  ----------
                                     56,590      49,591
                                  ----------  ----------


STOCKHOLDERS' EQUITY

Capital Stock
  Authorized:
    100,000,000 Common shares,
    par value $0.001 per share

  Issued and outstanding:
    12,025,000 Common shares         12,025      12,025

  Additional paid-in capital        417,975     417,975

Deficit Accumulated During The
Development Stage                  (306,240)   (183,278)
                                  ----------  ----------

                                    123,760     246,722
Less:  Subscriptions Receivable           -     (80,160)
                                  ----------  ----------
                                    123,760     166,562
                                  ----------  ----------
                                  $ 180,350   $ 216,153
=========================================================


Nature Of Operations (Note 2)

</TABLE>



<PAGE>


                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                   CONSOLIDATED STATEMENT OF LOSS AND DEFICIT
                                   (Unaudited)
                            (Stated in U.S. Dollars)


<TABLE>
<CAPTION>


                                                            INCEPTION
                                                               MAY 26
                                       THREE MONTHS ENDED     2000 TO
                                          NOVEMBER 30     NOVEMBER 30
                                      2002          2001         2002
                                   -----------------------------------
                                           2002          2001       2002
                                     -----------------------------------
<S>                                 <C>           <C>           <C>
Expenses
  Amortization                      $       916   $         -   $  2,247
  Consulting fees                        50,906        13,000     94,342
  General and administrative             18,830           413     30,902
  Investor relations                     20,132             -     23,322
  Mineral property option payments            -             -     15,500
  Mineral property exploration
   expenditures                               -         4,000     12,273
  Professional fees                      31,379         3,797    124,622
  Stock transfer fees                       799             -      3,032
                                    -------------------------------------
Net Loss For The Period                 122,962        21,210   $306,240
                                                                =========


Deficit Accumulated During
 The Exploration Stage,
 Beginning Of Period                    183,278        92,275
                                      ------------------------
Deficit Accumulated During
 The Exploration Stage,
 End Of Period                      $   306,240   $   113,485
==============================================================

Basic And Diluted
 Loss Per Share                     $     (0.01)  $     (0.01)
==============================================================


Weighted Average Number
 of Shares Outstanding               12,025,000    11,575,000
==============================================================


</TABLE>




<PAGE>



                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                      CONSOLIDATED STATEMENT OF CASH FLOWS
                                   (Unaudited)
                            (Stated in U.S. Dollars)


<TABLE>
<CAPTION>




--------------------------------------------------------------

                                                    INCEPTION
                                                       MAY 26
                               THREE MONTHS ENDED     2000 TO
                                  NOVEMBER 30     NOVEMBER 30
                                2002       2001        2002
--------------------------------------------------------------
<S>                          <C>         <C>        <C>
Cash Flows From Operating
 Activity
  Net loss for the period    $(122,962)  $(21,210)  $(306,240)
  Item not involving cash:
  Amortization                     916          -       2,247

Adjustments To Reconcile
 Net Loss To Net Cash
 Used By Operating Activity
  Prepaid expenses                 466          -      (1,088)
  Advances receivable           (1,500)         -      (1,500)
  Accounts payable and
   accrued liabilities         (13,001)     1,046      36,590
                             ---------------------------------

                              (136,081)   (20,164)   (269,991)
                             ---------------------------------


Cash Flows From
 Financing Activity
  Share capital issued          80,160          -     430,000
  Advances from shareholder     20,000          -      20,000
                             ---------------------------------


                               100,160          -     450,000
                             ---------------------------------


Cash Flows From
 Investing Activity
  Purchase of equipment        (15,425)    (2,481)    (27,747)
  Patent acquisitions          (20,000)         -     (40,000)
                             ---------------------------------

                               (35,425)    (2,481)    (67,747)
                             ---------------------------------



(Decrease) Increase In
 Cash                          (71,346)   (22,645)    112,262

Cash,
 Beginning Of Period           183,608     23,592           -
                             ---------------------------------

Cash,
 End Of Period                $ 112,262   $    947   $ 112,262
===============================================================
</TABLE>



<PAGE>



                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                 CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

                                NOVEMBER 30, 2002
                                   (Unaudited)
                            (Stated in U.S. Dollars)


<TABLE>
<CAPTION>

--------------------------------------------------------------------------------

                                     COMMON STOCK
                          ---------------------------------
                                                ADDITIONAL
                                                PAID-IN

                           SHARES      AMOUNT   CAPITAL   DEFICIT     TOTAL
--------------------------------------------------------------------------------


<S>                       <C>         <C>      <C>       <C>         <C>
Shares issued for
 cash at $0.001
 (May 2000)                 7,500,000  $ 7,500  $      -  $       -   $   7,500


Shares issued for
 cash at $0.01
 (June 2000)                4,000,000    4,000    36,000          -      40,000

Shares issued for
 cash at  $0.10
 (August 2000)                 75,000       75     7,425          -       7,500

Net loss for the period             -        -         -    (17,927)    (17,927)
                          ------------------------------------------------------
Balance,
 August 31, 2000           11,575,000   11,575    43,425    (17,927)     37,073

Net loss for
 the year                           -        -         -    (74,348)    (74,348)
                          ------------------------------------------------------
Balance,
 August 31, 2001           11,575,000   11,575    43,425    (92,275)    (37,275)

Shares issued for
 cash at $0.50
 (August 2002)                150,000      150    74,850          -      75,000

Shares issued for
 cash at $1.00
 (August 2002)                300,000      300   299,700          -     300,000

Net loss for
 the year                           -        -         -    (91,003)    (91,003)
                          ------------------------------------------------------
Balance,
 August 31, 2002           12,025,000   12,025   417,975   (183,278)    246,722

Net loss for
 the period                         -        -         -   (122,962)   (122,962)
                          ------------------------------------------------------
Balance,
 November 30, 2002        12,025,000  $12,025  $417,975  $(306,240)  $ 123,760
                          ======================================================

</TABLE>




<PAGE>



                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2002
                                   (Unaudited)
                            (Stated in U.S. Dollars)



1.     BASIS  OF  PRESENTATION

The unaudited consolidated financial statements as of November 30, 2002 included
herein have been prepared without audit pursuant to the rules and regulations of
the  Securities  and  Exchange  Commission.  Certain  information  and  footnote
disclosures  normally  included  in  financial statements prepared in accordance
with  United States generally accepted principles have been condensed or omitted
pursuant  to  such  rules  and  regulations.  In  the opinion of management, all
adjustments (consisting of normal recurring accruals) considered necessary for a
fair  presentation  have  been  included.  It  is suggested that these financial
statements  be  read  in  conjunction with the August 31, 2002 audited financial
statements  and  notes  thereto.


2.     NATURE  OF  OPERATIONS

a)     Organization

The  Company  was  incorporated in the State of Nevada, U.S.A., on May 26, 2000.

b)     Development  Stage  Activities

Coyote  Ventures  Corp. (the "Company") is currently a development stage company
under the provisions of Statement of Financial Accounting Standards ("SFAS") No.
7.  The  Company  is engaged in the business of developing technology related to
cancer  imaging  systems and conducts business under the name "August Biomedical
Corporation".

During  the  period  ended  November  30,  2002,  the  Company  incorporated  a
wholly-owned British Columbia subsidiary, August Research Corp., to complete the
development  of  the  technology.

In  prior  years,  the Company had been primarily engaged in the acquisition and
exploration  of  mining  properties,  and was classified as an exploration stage
company.

c)     Going  Concern

The  accompanying  financial  statements have been prepared assuming the Company
will  continue  as  a  going  concern.



<PAGE>




                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2002
                                   (Unaudited)
                            (Stated in U.S. Dollars)



2.     NATURE  OF  OPERATIONS  (Continued)

c)     Going  Concern  (Continued)

As  shown  in  the accompanying financial statements, the Company has incurred a
net  loss  of  $306,240 for the period from May 26, 2000 (inception) to November
30,  2002,  and  has  no sales.  The future of the Company is dependent upon its
ability  to  obtain  financing  and  upon  future profitable operations from the
development  of its technology.  Management has plans to seek additional capital
through  a  private  placement  and  public  offering  of its common stock.  The
financial  statements  do  not  include  any  adjustments  relating  to  the
recoverability  and  classification  of  recorded  assets, or the amounts of and
classification  of  liabilities that might be necessary in the event the Company
cannot  continue  in  existence.


3.     SIGNIFICANT  ACCOUNTING  POLICIES

The  financial  statements  of the Company have been prepared in accordance with
generally  accepted  accounting  principles  in  the  United  States.  Because a
precise  determination  of  many assets and liabilities is dependent upon future
events,  the  preparation  of  financial  statements  for  a  period necessarily
involves  the  use  of  estimates  which have been made using careful judgement.

The  financial  statements have, in management's opinion, been properly prepared
within  reasonable  limits  of  materiality  and  within  the  framework  of the
significant  accounting  policies  summarized  below:

a)     Consolidation

These  financial  statements  include  the  accounts  of  the  Company  and  its
wholly-owned  subsidiaries,  Coyote-Flint  Exploration Corp. and August Research
Corp.,  both  British  Columbia  corporations.

b)     Equipment

Equipment  is recorded at cost.  Amortization of office equipment and laboratory
equipment  is calculated on a straight-line basis at annual rates of 30% and 20%
respectively.


<PAGE>




                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2002
                                   (Unaudited)
                            (Stated in U.S. Dollars)



3.     SIGNIFICANT  ACCOUNTING  POLICIES  (Continued)

c)     Intangible  Asset

The  Company continually monitors its intangible assets to determine whether any
impairment  has  occurred.  In  making  such determination with respect to these
assets,  the  Company  evaluates  the  performance  on an undiscounted cash flow
basis,  of  the  intangible  assets  or  group  of assets, which gave rise to an
asset's  carrying  amount.  Should  impairment  be  identified,  a loss would be
reported  to  the extent that the carrying value of the related intangible asset
exceeds  the  fair value of that intangible asset using the discounted cash flow
method.  The  Company has not amortized intangible assets as operations have not
commenced.

d)     Use  of  Estimates

The  preparation  of  financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of  assets  and  liabilities,  and disclosure of
contingent  assets  and liabilities at the date of the financial statements, and
the  reported amounts of revenues and expenses for the reporting period.  Actual
results  could  differ  from  these  estimates.

e)     Foreign  Currency  Translation

The  Company's  functional currency is the U.S. dollar.  Transactions in foreign
currency  are  translated  into  U.S.  dollars  as  follows:

i)     monetary  items  at  the  rate  prevailing  at  the  balance  sheet date;
ii)     non-monetary  items  at  the  historical  exchange  rate;
iii)     revenue and expense at the average rate in effect during the applicable
accounting  period.

f)     Stock  Based  Compensation

The  Company  accounts  for  stock  based  employee  and  director  compensation
arrangements  in  accordance  with  provisions  of  Accounting  Principles Board
("APB") Opinion No. 25 - "Accounting for Stock Issued to Employees", and related
interpretations,  and  complies with the disclosure provisions of SFAS No. 123 -
"Accounting  for  Stock  Based  Compensation".  Under  APB  No. 25, compensation
expense  is  based  on  the difference, if any, on the date the number of shares
receivable  is  determined,  between  the  estimated fair value of the Company's
stock  and  the  exercise  price  of options to purchase that stock. Stock based
compensation  arrangements  for  others  are recorded at their fair value as the
services  are  provided  and  the  compensation  earned.

<PAGE>



                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2002
                                   (Unaudited)
                            (Stated in U.S. Dollars)



3.     SIGNIFICANT  ACCOUNTING  POLICIES  (Continued)

g)     Income  Taxes



The  Company  has  adopted Statement of Financial Accounting Standards No. 109 -
"Accounting  for Income taxes" (SFAS 109).  This standard requires the use of an
asset  and  liability approach for financial accounting, and reporting on income
taxes.  If it is more likely than not that some portion or all of a deferred tax
asset  will  not  be  realized,  a  valuation  allowance  is  recognized.

h)     Basic  and  Diluted  Loss  Per  Share

In  accordance  with  SFAS  No.  128  - "Earnings Per Share", the basic loss per
common  share  is computed by dividing net loss available to common stockholders
by  the  weighted average number of common shares outstanding.  Diluted loss per
common  share is computed similar to basic loss per common share except that the
denominator  is increased to include the number of additional common shares that
would  have  been outstanding if the potential common shares had been issued and
if  the additional common shares were dilutive.  At August 30, 2002, the Company
has  no  common  stock  equivalents  that were anti-dilutive and excluded in the
earnings  per  share  computation.

I)     Mineral  Property  Option  Payments  and  Exploration  Costs

The  Company  expenses  all  costs related to the maintenance and exploration of
mineral claims in which it has secured exploration rights prior to establishment
of  proven  and probable reserves.  To date, the Company has not established the
commercial  feasibility  of  its exploration prospects, therefore, all costs are
being  expensed.


4.     EQUIPMENT
<TABLE>
<CAPTION>


                              NOVEMBER 30     AUGUST 31
                                   2002      2002
                              -------------------------
<S>                              <C>       <C>
Office equipment                 $ 2,481   $    2,481
Laboratory equipment              25,265        9,841
                              -----------------------
                                  27,746       12,322
Less:  Accumulated amortization   (2,246)      (1,331)
                              -------------------------

                                 $25,500   $   10,991
                              =========================

</TABLE>


<PAGE>


                              COYOTE VENTURES CORP.
                          (A Development Stage Company)

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                NOVEMBER 30, 2002
                                   (Unaudited)
                            (Stated in U.S. Dollars)



5.     INTANGIBLE  ASSETS

(i)  Pursuant  to a sale agreement dated August 16, 2002, the Company acquired a
     United States Patent for direct viewing of induced tissue fluorescence by a
     human  viewer  through  an  endoscope (the "Technology"). The Technology is
     subject  to  a  royalty  of  0.75% in favour of the British Columbia Cancer
     Foundation.

     In  addition,  the  acquisition  is  subject  to  a provision requiring the
     Company  to  return the Technology to the vendor should the Company fail to
     complete  financing to raise net proceeds of $200,000 within 90 days of the
     agreement,  and  a  further  $800,000 within 180 days of the agreement. The
     Company has fulfilled the first provision by completing a private placement
     of  300,000  common  shares  at  $1.00  per  share  prior  to  year  end.

(ii) The  Company  entered in an option agreement to acquire certain patents for
     cash  consideration  of  $20,000  upon signing, and $180,000 by January 30,
     2003.


6.     CONTINGENCY

Intangible  Asset

The  Company's  intangible  asset has been acquired pursuant to a sale agreement
subject  to  certain financing conditions.  In order to retain its interest, the
Company  must  satisfy  the  terms  of  the  sale agreement described in Note 5.


7.     STOCK  OPTION  PLAN

The  Company  adopted  a  stock  option  plan (the "Plan") pursuant to which the
directors may grant a maximum of 1,736,250 common stock options to officers, key
employees and consultants.  The Company granted 1,735,000 fully vested incentive
stock  options  allowing the holders to purchase one common share of the Company
at  $2.50  per  share  for  a  term  expiring  September  9,  2004.



<PAGE>

Item  2.  Management's  Discussion  and  Analysis  or  Plan  of  Operations

Plan  of  Operations:
---------------------

The  Company  is  currently  in  the development stage of its technology and has
forecast the expenditure of approximately 2.5 million dollars during the next 12
months,  primarily  for  the  purpose  of:

     *    Expansion  of  its  internal  management  and research and development
          staff;

     *    Development  of  prototypes to provide proof of principal for both the
          cervical  cancer  and  oral  cancer  detection  systems;

     *    Conducting  pilot  clinical  studies  and  the  initiation  of a large
          multi-center  clinical  trial  of  the  CERVeyor  System in the United
          States  and  Canada;  and

     *    Conducting pilot clinical studies and the initiation of a multi-center
          trial  of  its  ORALview  device  in  the  United  States  and Canada.

Following  successful  completion  of  these  clinical  trials  the Company will
aggressively  pursue  strategic  marketing  partners  for the worldwide sale and
distribution  of  the  Company's  proprietary  technology.

The  Company  does  not  anticipate  purchasing any real property or significant
equipment during the next 12 months.  We plan on conducting our clinical studies
in  partnership  with  physicians  who  have  an  interest  in  our  proprietary
technology.  Our  clinical  studies will be conducted in facilities available to
those  physicians.

At the present time we have only one employee and primarily further our business
pursuits  through  the  use  of  consultants.  We  anticipate hiring several key
employees in early 2003.  Additional employees will be hired upon the successful
conclusion  of  our  clinical  studies  and  as  our  funding allows.  We cannot
determine  at  this  time  how  soon  additional  employees  will  be  hired.

At  November  30, 2002, the Company had cash of $112,262.  To meet the projected
cash  flow needs of the Company, the board of directors has approved the private
placement  of  3,000,000  millions units at $2.00 per unit for total proceeds of
$6,000,000.  Each unit will consist of one share of common stock and one warrant
to purchase one share of common stock at the exercise price of $3.00, subject to
adjustment.  The  warrants  will  have  an exercise term of 18 months.  Until we
obtain  the  use  of  proceeds  from  this private placement, we have sufficient
capital  to  pursue  our  business  plan  for  approximately  90  days.




FORWARD  LOOKING  STATEMENTS

The  information  in  this discussion contains forward-looking statements within
the  meaning  of  Section  27A  of  the  Securities Act of 1933, as amended, and
Section  21E  of  the  Securities  Exchange  Act  of  1934,  as  amended.  These
forward-looking statements involve risks and uncertainties, including statements
regarding  the  Company's capital needs, business strategy and expectations. Any
statements  contained  herein that are not statements of historical facts may be

                                       3

<PAGE>


deemed  to  be  forward-looking  statements.  In  some  cases,  you can identify
forward-looking  statements  by  terminology  such  as  "may", "will", "should",
"expect",  "plan",  "intend",  "anticipate",  "believe",  "estimate", "predict",
"potential"  or  "continue",  the  negative  of  such  terms or other comparable
terminology. Actual events or results may differ materially. In evaluating these
statements,  you  should  consider various factors, including the risks outlined
below,  and, from time to time, in other reports the Company files with the SEC.
These  factors  may cause the Company's actual results to differ materially from
any  forward-looking statement. The Company disclaims any obligation to publicly
update  these  statements, or disclose any difference between its actual results
and  those  reflected  in  these  statements.  The  information  constitutes
forward-looking  statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act  of  1995.


ITEM  3.     CONTROLS  AND  PROCEDURES.

As  required  by  Rule  13a-14  under  the  Securities Exchange Act of 1934 (the
"Exchange Act"), we carried out an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures within the 90 days prior
to  the  filing  date of this report.  This evaluation was carried out under the
supervision and with the participation of our Chief Executive Officer, Mr. Scott
C.  Houghton  and Chief Financial Officer, Ms. Korina Houghton.  Based upon that
evaluation,  our  Chief  Executive Officer and Chief Financial Officer concluded
that  our  disclosure  controls  and procedures are effective in timely alerting
management  to  material  information  relating  to  us  which is required to be
included in our periodic SEC filings.  There have been no significant changes in
our  internal  controls  or  in  other  factors  that could significantly affect
internal  controls  subsequent  to  the  date  we  carried  out  our evaluation.

Disclosure  controls  and  procedures are controls and other procedures that are
designed  to  ensure that information required to be disclosed our reports filed
or  submitted  under  the  Exchange  Act  is recorded, processed, summarized and
reported,  within  the  time  periods  specified  in the Securities and Exchange
Commission's  rules  and  forms.  Disclosure  controls  and  procedures include,
without  limitation, controls and procedures designed to ensure that information
required  to  be  disclosed  in  our  reports  filed  under  the Exchange Act is
accumulated  and  communicated  to  management,  including  our  Chief Executive
Officer  and  Chief  Financial  Officer,  to  allow  timely  decisions regarding
required  disclosure.



PART  II  -  OTHER  INFORMATION


Item  1.  Legal  Proceedings

We  are  not  a party to any material legal proceedings and to our knowledge, no
such  proceedings  are  threatened  or  contemplated.


Item  2.  Changes  in  Securities

We  did not complete any sales of our securities during the fiscal quarter ended
November  30,  2002.

                                       4

<PAGE>


Item  3.  Defaults  upon  Senior  Securities

None.


Item  4.  Submission  of  Matters  to  a  Vote  of  Security  Holders

On  December  6, 2002, the Board of Directors of Coyote Ventures Corp., a Nevada
corporation  ("Coyote  Ventures"),  furnished  an  information  statement  to
stockholders to inform them of proposed majority shareholder action to amend the
Articles of Incorporation of the Company for the purpose of changing the name of
Coyote  Ventures  Corp.  to  August  Biomedical Corporation.  Shareholder action
approving  the  name  change  was  taken  on  or  about  December  26,  2002.


Item  5.  Other  Information

None.


Item  6.  Exhibits  and  Reports  on  Form  8-K.



EXHIBITS  REQUIRED  BY  ITEM  601  OF  REGULATION  SB


--------------------------------------------------------------------------------
Exhibit   ----------------------------------------------------------------------
Number    Description of Exhibit
--------  ----------------------------------------------------------------------
 99.1     Certification of Chief Executive Officer pursuant to 18 U.S.C. Section
          1350,  as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
          2002  (1)

 99.2     Certification of Chief Financial Officer pursuant to 18 U.S.C. Section
          1350,  as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
          2002  (2)
--------------------------------------------------------------------------------

(1)       Filed  as  an  Exhibit  to  this  Quarterly  Report  on  Form  10-QSB
(2)       Filed  as  an  Exhibit  to  this  Quarterly  Report  on  Form  10-QSB
--------------------------------------------------------------------------------


REPORTS  ON  FORM  8-K

We  did not file any Current Reports on Form 8-K during the fiscal quarter ended
November  30,  2002.

                                       5

<PAGE>


                                   SIGNATURES

In  accordance with the requirements of the Securities and Exchange Act of 1934,
the  Registrant  has  duly  caused this report to be signed on its behalf by the
undersigned,  thereunto  duly  authorized.

AUGUST  BIOMEDICAL  CORPORATION

Date:     January  21,  2003



By:  /s/ Scott C. Houghton
    ---------------------------
     Scott C. Houghton
     President
     Principal  Executive  Officer
     Principal  Accounting  Officer

                                       6

<PAGE>




                                 CERTIFICATIONS

I,  Scott  C.  Houghton,  certify  that;

(1)  I  have  reviewed  this quarterly report on Form10-QSB of August Biomedical
     Corporation;

(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of a material fact or omit to state a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;

(3)  Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  Registrant  as  of,  and for, the periods presented in this
     quarterly  report;

(4)  The  Registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the Registrant and have:

     a)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  Registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;

     b)   evaluated  the  effectiveness  of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  quarterly  report  (the  "Evaluation  Date");  and

     c)   presented  in  this  quarterly  report  our  conclusions  about  the
          effectiveness  of  the disclosure controls and procedures based on our
          evaluation  as  of  the  Evaluation  Date;

(5)  The  Registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the Registrant's auditors and the audit
     committee  of  Registrant's  board  of directors (or persons performing the
     equivalent  functions):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which  could  adversely  affect  the Registrant's ability to
          record,  process,  summarize  and  report  financial  data  and  have
          identified  for  the  Registrant's auditors any material weaknesses in
          internal  controls;  and

     b)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the Registrant's internal
          controls;  and

(6)  The  Registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  facts  that  could  significantly  affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date:   January  21,  2003         /s/ Scott C. Houghton
                                   ___________________________________
                                   Scott  C.  Houghton
                                   Chief  Executive  Officer

<PAGE>

                                 CERTIFICATIONS

I,  Korina  Houghton,  certify  that;

(7)  I  have  reviewed  this quarterly report on Form10-QSB of August Biomedical
     Corporation;

(8)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of a material fact or omit to state a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;

(9)  Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  Registrant  as  of,  and for, the periods presented in this
     quarterly  report;

(10) The  Registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the Registrant and have:

     d)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  Registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;

     e)   evaluated  the  effectiveness  of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  quarterly  report  (the  "Evaluation  Date");  and

     f)   presented  in  this  quarterly  report  our  conclusions  about  the
          effectiveness  of  the disclosure controls and procedures based on our
          evaluation  as  of  the  Evaluation  Date;

(11) The  Registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the Registrant's auditors and the audit
     committee  of  Registrant's  board  of directors (or persons performing the
     equivalent  functions):

     c)   all  significant  deficiencies  in the design or operation of internal
          controls  which  could  adversely  affect  the Registrant's ability to
          record,  process,  summarize  and  report  financial  data  and  have
          identified  for  the  Registrant's auditors any material weaknesses in
          internal  controls;  and

     d)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the Registrant's internal
          controls;  and

(12) The  Registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  facts  that  could  significantly  affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date:   January  21,  2003         /s/ Korina Houghton
                                   ___________________________________
                                   Korina Houghton
                                   Chief  Financial  Officer